Skip to main
DBD

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf has demonstrated strong growth in its Retail segment, with revenues of $255 million, reflecting an 8.1% quarter-over-quarter increase and a 7.8% year-over-year increase, while gross margins expanded by 100 basis points to 24.7%. The company is on track to achieve free cash flow in the range of $190 million to $210 million by 2025, up from $109 million in 2024, alongside consistent positive free cash flow generation for four consecutive quarters. With anticipated robust year-over-year EPS growth in 2026 and planned margin expansions, Diebold Nixdorf is well-positioned for ongoing financial improvement and investor interest.

Bears say

Diebold Nixdorf Inc faces a negative outlook due to several fundamental challenges, including technological missteps and failure to innovate, potentially resulting in declining revenues and profitability. The Banking segment's gross margins have shown a slight decline quarter-over-quarter, indicating increased pricing pressure and heightened competition, which could adversely affect the company's financial stability. Additionally, the reliance on cost-saving measures and management's anticipated operational expenditure reductions may not sufficiently address ongoing risks such as tariff impacts, supply chain disruptions, and currency volatility, further complicating the company's financial outlook.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.